New drug combo shows promise for Hard-to-Treat blood cancers
NCT ID NCT07153497
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 36 times
Summary
This study tests whether adding the drug olutasidenib to standard treatments helps people with certain types of blood cancer (MDS or AML) that have an IDH1 gene mutation. About 132 adults will take part. The goal is to see if the new combination leads to higher remission rates and better blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.